Filtered By:
Condition: Atrial Fibrillation
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 1538 results found since Jan 2013.

Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients
Cardiol Res Pract. 2021 Feb 8;2021:6657776. doi: 10.1155/2021/6657776. eCollection 2021.ABSTRACTIn recent years, significant changes in stroke prophylaxis in patients with atrial fibrillation (AF) have been observed. Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used in the prevention of thromboembolic complications in patients with AF. The aim of the study was to evaluate recommended stroke prophylaxis in patients with AF and to identify predictors of using NOACs in patients treated with anticoagulant therapy. The present study was a retrospective, observational, single-center study which included...
Source: Cardiology Research and Practice - February 25, 2021 Category: Cardiology Authors: B Bielecka I Gorczyca O Jelonek B Wo żakowska-Kapłon Source Type: research

Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview
J Cardiol. 2022 Nov 15:S0914-5087(22)00277-5. doi: 10.1016/j.jjcc.2022.11.006. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagoni...
Source: Journal of Cardiology - November 18, 2022 Category: Cardiology Authors: Hiroshi Ueno Teruhiko Imamura Shuhei Tanaka Nobuyuki Fukuda Koichiro Kinugawa Source Type: research

DOACs or Vitamin K Antagonists for Patients ≥ 85 With AF and Recent Stroke? DOACs or Vitamin K Antagonists for Patients ≥ 85 With AF and Recent Stroke?
Until recently, clinicians had little evidence to guide their decisions about the most effective and safe treatment for the oldest patients with atrial fibrillation and recent stroke.Medscape Medical News
Source: Medscape Internal Medicine Headlines - January 3, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research

Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis
ConclusionsBased on current evidence, for stroke prevention in patients with AF, the safest DOAC is apixaban in terms of non-major bleeding. This suggests that apixaban may have a lower risk of non-major bleeding than other anticoagulants and may help provide some clinical reference for choosing a more appropriate drug for the patient.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

Vitamin K Antagonists-Associated Cerebral Hemorrhages: What Are Their Characteristics? Original Contributions
Conclusions— A similar anatomic distribution of ICH in patients with or without VKAs suggests that VKAs should not be considered as a cause of ICH because both locations are usually due to different vasculopathies (deep perforating arteries vasculopathy in deep and cerebral amyloid angiopathy in lobar). The different impact of VKAs on ICH volumes according to location suggests a different susceptibility of these vasculopathies to VKAs. This finding may lead to specific therapeutic strategies.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Dequatre-Ponchelle, N., Henon, H., Pasquini, M., Rutgers, M. P., Bordet, R., Leys, D., Cordonnier, C. Tags: Cerebrovascular disease/stroke, Intracerebral Hemorrhage Original Contributions Source Type: research

Inadequate anticoagulation by Vitamin K antagonists and major adverse cardiovascular events other than stroke
I read the article by Pastori et al. [1] with great interest. In their artcile, the authors reported that inadequate anticoagulation by Vitamin K Antagonists was found to be associated with Major Adverse Cardiovascular Events (MACE) in patients with atrial fibrillation, and they concluded that time in therapeutic range (TTR) was an independent predictor of MACE in patients with atrial fibrillation. It is known that inadequate anticoagulation by Vitamin K Antagonists is a strong predictor of stroke.
Source: International Journal of Cardiology - October 30, 2015 Category: Cardiology Authors: Mehmet Eyuboglu Tags: Correspondence Source Type: research

Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
PMID: 27307147 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 15, 2016 Category: Hematology Authors: Wilson MR, Parakramawansha R, Quinn TJ, Tait RC Tags: Thromb Haemost Source Type: research

Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non-Vitamin K Anticoagulants: Misleading and Obsolete, at least for the Low-Risk Patients?
Abstract The thromboembolic risk of atrial fibrillation (AF) is significantly mitigated by oral anticoagulation (OAC) therapy, albeit at an increasing bleeding risk. The general principle is that the expected protective benefit of OAC must not exceed the potential harm conferred by possible bleeding. Over the recent years, the CHA2DS2-VASc score has been proven to be superior to other scores in identifying 'low risk' AF patients. However, even this latest score does not incorporate all possible risk factors causing a high thromboembolic risk, while the individual components of the CHA2DS2-VASc score do not seem to...
Source: Current Drug Targets - September 4, 2016 Category: Drugs & Pharmacology Authors: Manolis AS, Manolis TA, Manolis AA, Melita H Tags: Curr Drug Targets Source Type: research

Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
PMID: 28264892 [PubMed - in process]
Source: Circulation - March 6, 2017 Category: Cardiology Authors: Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR, ROCKET AF Steering Committee and Investigators Tags: Circulation Source Type: research

Appropriate dosing of non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
The development of non-Vitamin K antagonist oral anticoagulants (NOACs) has been a major advance in therapy for patients requiring oral anticoagulation, particularly for long-term indications such as stroke prevention in atrial fibrillation (AF). The NOACs are generally easier to dose and manage due to less heterogeneity of effect across individuals and fewer drug and food interactions, compared with warfarin. However, the treatment effect of NOACs may vary based on important patient characteristics, particularly renal function.
Source: Trends in Cardiovascular Medicine - June 19, 2017 Category: Cardiology Authors: Benjamin A. Steinberg, Jeffrey B. Washam Source Type: research

Contemporary Management of Stroke Prevention in Atrial Fibrillation Following the European Society of Cardiology Guidelines
Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Source: Radcliffe Cardiology - August 14, 2017 Category: Cardiology Authors: mehul Source Type: research